On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
...IDS Relief (PEPFAR) through the Centers for
Disease Control and Prevention, lpath
has been building over 30
community-based organizations' technical and orga... capacity and
information sharing and referral mechanisms. Since inception, lpath
improved service provision for nearly 300,000 Kenyans in HIV prevention...
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
...tform technology. Based on this positive outcome, lpath
will collaborate with DataMabs of
London, England,... an antibody against another
bioactive lipid, S1P. lpath
humanized the antibody in 2006 and plans to
as an important new area of drug discovery. lpath
was one of the first
companies to recognize that b...
Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
... development. "The favorable findings will
with considerable dosing flexibility in our upcoming Phase I
clinical trials." lpath
plans to file an IND in November of 2007 for clini...cancer patients. During the first quarter of 2008, lpath
to file a second IND, this one for clinical ...
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug
...tributes significantly to
AMD-related vision loss. lpath
has demonstrated in previous studies
that Sphingom... is extremely well
positioned in the AMD arena."
plans to initiate clinical trials for wet AMD in early
Lpath, Inc., headquartered in San Diego, Califor...
AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
..., has directed research and
development programs for a number of early stage biotech companies such as
Centaur Pharmaceuticals, Atairgin Technologies, lpath
(LPTN.OB) and Tosk in addition to AngioGenex. He was also instrumental in
raising capital for those companies. His career highlight...